<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: This multicenter phase II study determined the efficacy and safety of new daily oral S-1 and weekly irinotecan (<z:chebi fb="9" ids="27656">CPT</z:chebi>-11) combination schedule in patients with previously untreated advanced or <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Patients received first-line chemotherapy comprising S-1 80 mg/m(2)/day given on days 3 to 7, 10 to 14, and 17 to 21 and 60 mg/m(2) <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 administered intravenously on days 1, 8, and 15 of a 28-day cycle </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: A total of 45 eligible patients were enrolled in this study </plain></SENT>
<SENT sid="3" pm="."><plain>The overall response rate was 48.9% </plain></SENT>
<SENT sid="4" pm="."><plain>Median progression-free survival and median overall survival was 8.1 months and 20.9 months, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The rates of grade 3 or 4 toxicity were as follows: <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, 8.9%; <z:hpo ids='HP_0001903'>anemia</z:hpo>, 4.4%; <z:hpo ids='HP_0002039'>anorexia</z:hpo>, 6.7%; and <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, 6.7% </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: This new S-1 and irinotecan combination schedule appeared to be an effective, well-tolerated, and convenient regimen in patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> as compared with conventional regimens such as FOLFIRI and IRIS </plain></SENT>
</text></document>